NORTHVALE, N.J.--(BUSINESS WIRE)--Elite Pharmaceuticals, Inc. (AMEX: ELI), a leading drug delivery, specialty pharmaceutical company focused primarily on developing and commercializing proprietary abuse resistant, extended release pain compounds, today announced that the Company will be presenting clinical data on the dose-response reduction of opioid-induced euphoria from naltrexone, at the American Academy of Pain Medicine’s (AAPM) 24th Annual Meeting taking place at the Gaylord Palms Resort in Orlando, FL on February 14-16.
